Knopp Biosciences to Present Details of Positive Results From the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021
13.5.2021 13:00:00 EEST | Business Wire | Press release
Knopp Biosciences LLC today announced it will present detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma in a virtual poster session at the ATS 2021 International Conference.
“We look forward to sharing comprehensive results of the EXHALE trial, which underscore the readiness of dexpramipexole for further development in eosinophilic asthma,” said Michael Bozik, M.D., president and CEO of Knopp. “Monoclonal antibody treatments approved for asthma demonstrate that reduction in eosinophils is associated with significantly improved outcomes, but the need remains for an oral alternative in the eosinophilic asthma treatment paradigm.”
Following are details of the poster presentation:
|
Poster Title |
Abstract Number / Presentation Details |
|
|
Oral Dexpramipexole Efficacy in Lowering Blood Eosinophils in Patients with Moderate to Severe Uncontrolled Eosinophilic Asthma
|
A1359 Poster Presentation
Presenter: Calman Prussin, M.D., VP, Clinical and Translational Medicine, Knopp Biosciences LLC
Time: 8 a.m. EDT
|
Follow Knopp Biosciences on Twitter via @KnoppBio and keep up to date with conference news and updates using the hashtag #ATS2021.
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small-molecule treatments for developmental and epileptic encephalopathies, other epilepsies, neuropathic pain, and tinnitus. Please visit www.knoppbio.com.
ABOUT DEXPRAMIPEXOLE
Dexpramipexole, a selective inhibitor of eosinophil maturation, is an oral small molecule drug in development by Knopp for asthma and other eosinophil-associated diseases. In hypereosinophilic syndrome, dexpramipexole has previously been shown in a Phase 2 trial to significantly reduce requirements for oral corticosteroids and in a subset of patients to produce durable disease remission. In its earlier development in amyotrophic lateral sclerosis, dexpramipexole was shown to be well tolerated in Phase 1, Phase 2, and Phase 3 trials comprising approximately 1,200 patients.
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events, or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing pre-clinical or clinical study to verify their safety and effectiveness.
Media inquiries:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005183/en/
Contact information
Tom Petzinger
tom@knoppbio.com
412-488-1776
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cyclic Materials Opens America’s First Commercial-Scale Facility Delivering Automated Rare Earth Magnet Recovery9.9.2026 23:09:00 EEST | Press release
Cyclic Materials announced today the opening of its first commercial-scale rare earth magnet recycling facility in Mesa, Arizona, marking a major milestone in building domestic supply of rare earths and critical minerals. With an annual processing capacity of up to 25,000 metric tons of magnet-bearing end-of-life products, the facility produces Cyclic’s rare earth magnet material, Mag-Xtract™, and critical minerals such as copper and aluminum, and steel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909142592/en/ Leaders gather to mark the opening of Cyclic Materials’ new facility in Mesa, Arizona. From left to right: Herbert Flores, Arizona Commerce Authority Vice President of Business Development; Scott Somers, City of Mesa Vice Mayor; Jeff Dawley, Cyclic Materials CFO; Mark Freeman, City of Mesa Mayor; Ahmad Ghahreman, Cyclic Materials Founder and CEO; William Kimmitt, U.S. Under Secretary of Commerce for Internationa
Belkin Introduces Titan SmartShield Pro Collection for the New iPhone 18 Pro Lineup9.9.2026 22:00:00 EEST | Press release
Belkin, a leading consumer electronics brand for over 40 years, today introduced its new Titan SmartShield Pro collection, designed to protect and enhance the experience of the new iPhone 18 Pro lineup. The collection includes three distinct screen protectors – clear, Blue-to-Red and Bright Privacy – each combining advanced Nano-Titan Technology with premium anti-reflective properties, exceptional scratch resistance and up to 9 feet of impact protection.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909094720/en/ Belkin Titan SmartShield Pro Blue-to-Red Light screen protector As smartphones become increasingly central to how people work, travel and connect, the Titan SmartShield Pro collection goes beyond traditional screen protection to address the different ways consumers use their devices throughout the day. Whether prioritizing crystal-clear viewing, greater visual privacy or a more comfortable screen experience, us
PPAI Releases Landmark Study Showing Branded Merchandise Supports a $472 Billion Global Economic Footprint9.9.2026 20:24:00 EEST | Press release
Branded merchandise connects brands and people every day, but its impact extends well beyond the products consumers wear, use, receive or purchase. A landmark study commissioned by Promotional Products Association International (PPAI) provides the first comprehensive look at the global economic ecosystem behind branded merchandise. Conducted by independent global advisory firm Oxford Economics, the Branded Merchandise Global Market Report measures the industry end to end, from manufacturing and decoration to distribution, retail, e-commerce, fulfillment, marketing and brand activation. Key findings: $338.3 billion was spent on branded merchandise globally in 2025. The industry supported $472.3 billion in global GDP. Branded merchandise supported 11.9 million jobs worldwide. The sector supported $141.3 billion in global tax revenues – roughly the same as the entire Swiss federal budget. “For years, we’ve known branded merchandise has an extraordinary ability to connect brands with peopl
Vindral Named Recipient of 2026 Technology & Engineering Emmy ® Award9.9.2026 19:38:00 EEST | Press release
Vindral, the Swedish company building future-ready technology for real-time audio and video, has been named a recipient of a 2026 Technology & Engineering Emmy® Award by the National Academy of Television Arts & Sciences (NATAS). Vindral is recognised in the category Web-Based Frame-Accurate Remote Monitoring Systems for Distributed Broadcast Production. The co-recipients in the category are SipRadius, NBCUniversal, Grass Valley, CBS Sports, Disney, Game Creek and Amazon. The awards will be presented on October 14 at the Television Academy's Saban Media Center in North Hollywood, California, where Vindral will be represented by CEO Daniel Alinder and Ian Jefferson. The Technology & Engineering Emmy® Award is one of the U.S. television industry's most prestigious recognitions of technical achievement, previously awarded to companies including Apple, Sony, Netflix and YouTube. This year's recipients are honoured for technology that enabled high-quality, real-time production from distribu
Elliptic Intelligence Used by the USSS to Take Action Against Xinbi, the $30 Billion Criminal Marketplace and Money Laundering Operation9.9.2026 19:36:00 EEST | Press release
Elliptic, the global leader in risk intelligence for on-chain finance, today confirmed that it provided the intelligence used by the United States Secret Service in action taken today against the Xinbi marketplace. The U.S. Secret Service froze wallets belonging to the marketplace and its merchants, containing $52.8 million in cryptoassets linked to Xinbi marketplace. Elliptic provided the data and intelligence that no other provider could. The data was extracted from Elliptic’s Data Fabric Solutions into the USSS' systems, giving investigators the one hundred thousand-foot view, connecting on-chain and off-chain data to paint a full picture of illicit activity rather than a snapshot in one screen of data. Data Fabric provides access to the same blockchain data and intelligence set behind Elliptic’s solutions, and that Elliptic’s own intelligence team used to expose both Huione and Xinbi before anyone else. Since beginning operations in 2022, Xinbi Guarantee and its merchants have proc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom